Heiner Dreismann joins Myriad's board
This article was originally published in Clinica
Molecular diagnostics specialist Myriad Genetics (Salt Lake City, Utah) has appointed Heiner Dreismann to its board of directors. Dr Dreismann has over 24 years of experience in the healthcare industry, and currently serves on the boards of several public and private companies in the sector. He worked for Roche from 1985 until 2006, where he held several positions, including President and CEO of its molecular systems division, and head of global business development of Roche Diagnostics. He was one of the early adopters of polymerase chain reaction (PCR) technology, which is now one of the most widely-used techniques in genetics research.